Hot or Not, Stock Market Edition: 08/21/2026

No duds today: these four stocks have accelerating growth, major catalysts, and Zen Ratings that put them among the stronger names in the market.

• 🔥 HOT: Century Aluminum (CENX) is reigniting the aluminum market 
• 🔥 HOT: National Energy Services Reunited (NESR) is still hot despite a 350% surge
• 🔥 HOT: Micron Technology (MU) is still undervalued after a 600% run
• 🔥 HOT: Fennec Pharmaceuticals (FENC) has an incredible moat 

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Century Aluminum (CENX) is restarting smelters that sat idle for over a decade, and the timing could hardly be better, with Washington policy making domestically produced aluminum considerably more valuable. Shares have nearly doubled in a year, yet the growth story underneath may still have room. Revenue is projected to expand at more than twice the industry pace, and earnings are forecast to grow roughly 4.5 times faster than peers — an unusual profile to find at a PEG ratio around 0.16. Analysts are firmly on board, with all three covering the stock recommending it as a Strong Buy and an average target implying more than 80% upside. (See analyst recommendations here.)

The Zen Ratings stop just short of an A. CENX earns a B in the Buy tier and ranks in the top 6% of everything we track, driven by top-2% Growth, top-3% Value, and top-4% Financials. Safety is the soft spot, which is what you'd expect from a cyclical aluminum producer. Idled capacity coming back online, policy tailwinds, explosive growth, and a bargain multiple make for a genuinely rare combination. 

🔥 HOT: National Energy Services Reunited (NESR) has already rallied more than 350% in a year, and somehow the numbers still say this thing isn't obviously expensive.

The company provides oilfield services across the Middle East and North Africa, where a large share of its growth is already contracted through deployments on major regional energy projects. Earnings more than doubled year over year, while a PEG ratio near 0.6 keeps the price reasonable against that expansion — and a DCF model puts fair value around $100 versus roughly $35 when the analysis was captured. 

The Zen Ratings reinforce it. NESR earns an overall A, ranking in the top 2% of all stocks we track, with Growth, Momentum, and Sentiment in the top 5%. What separates this from a typical momentum chart is that the growth behind it is contracted rather than hoped for. 

🔥 HOT: Everybody wants to own the AI boom. Micron Technology (MU) sells something that boom literally cannot function without. Micron produces the high-bandwidth memory feeding data to AI processors, and demand has run so hot that capacity is effectively sold out, with much of next year's production already committed. Earnings are forecast to grow more than 40% annually, the company has beaten estimates for 13 consecutive quarters, and the PEG ratio still sits near 0.5 (Anything below 1 is considered a screaming deal).

Wall Street's average target points to roughly 50% upside, while two elite top 1% analysts see room for shares to nearly double (See their takes here.) The Zen Ratings make an even stronger case: MU earns an A and ranks in the top 1% of every stock we track, with top-2% grades in both Growth and Financials. Safety is the blemish, since memory chips remain famously cyclical — but sold-out AI capacity paired with top-1% fundamentals is about as compelling as this sector gets. 

🔥 HOT: Fennec Pharmaceuticals (FENC) carries a market cap barely above $400 million, yet owns something that much bigger competitors crave: the first and only FDA-approved drug of its kind. 

Its medicine prevents permanent hearing loss caused by certain chemotherapy treatments, with patent protection running through 2039. Crucially, this isn't a pre-revenue biotech lottery ticket. Fennec has turned profitable, demand has hit record levels, and its most bullish analyst target implies upside above 50% (See all analyst recommendations here.)

Our model is enthusiastic. FENC earns an A and ranks in the top 2% of stocks we track, with Growth also in the top 2% and Sentiment at the very top of the scale. The caveat is Safety, since this remains a small pharma company leaning heavily on a single drug. That makes it speculative, sure. But a protected niche, real profitability, and smart money moving in is a combination worth watching closely. 

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.